In this cross-sectional study, we analysed serum concentrations of soluble markers of cellular immune activation, namely, interferon-γ, neopterin (a product of activated macrophages), soluble interleukin-2 receptor, and soluble CDS, in 25 patients with congestive heart failure. Ten (40%) patients showed increased concentrations (i.e. above the reference ranges of healthy controls) of neopterin, 14 (56%) showed increased soluble interleukin-2 receptor, and 6 (24%) showed increased soluble CDS. Endogenous interferon-γ was detectable in 10 patients (40%). In addition, we found significant correlations between neopterin and interferon-γ (rs = 0.417, p < 0.05), and between neopterin and soluble CDS concentrations (rs = 0.430, p < 0.05). All patients with increased soluble CDS also had increased soluble interleukin-2 receptor. However, no significant correlations of soluble interleukin-2 receptor with soluble CDS or any of the other quantities were observed.
Introduction
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and soluble CDS in the serum of patients.
Patients and Methods
Ten male patients (mean age 42 + 11 years) with dilated cardiomyopathy according to World Health Organization criteria (14) , and 15 patients with chronic myocarditis (14 males, one female, mean age 35 ± 13 years), referred'to the Cardiology Research Centre were studied. Eighteen patients underwent coronary angiography, none had significant coronary artery disease; endomyocardial biopsy was performed in 15 of the 18 patients. In one patient diagnosis was confirmed at necropsy. Eleven patients had histological evidence of chronic myocarditis. Clinically significant thromboembolic events were documented in eight patients.
Serum concentrations of neopterin were determined with a commercially available readioimmunoassay (IMMUtest, Henning, Berlin, Germany), using standard protocols provided by the manufacturer. Interferon-γ was quantified by radioimmunoassay (Centocor, Malvern, PA), employing an optimized application that allows detection of interferon-γ with enhanced sensitivity (13, 15) . This procedure includes two overnight incubation steps, and increases the sensitivity of the assay to a detection limit of 18 U/l. Radioactivity was counted with a gamma counter (CliniGamma 1272; Wallac Oy, Turku, Finland). Cell-free test enzyme immunoassays were used for measurements of soluble interleukin-2 receptor and soluble CDS (T Cell Sciences, Inc., Cambridge, MA) and quantification was performed using an ELISA-reader (Anthos, Labtec Instruments, Salzburg, Austria).
The concentrations of the analytes were compared with preestablished reference ranges of healthy controls which were provided by the manufacturers of the assays and proven by determinations on healthy volunteers in our laboratories (tab. 1).
Statistical evaluation was done by x*-test and Fishefs exact test for group comparisons, and Spearmarfs rank correlation coefficients (r s ) were computed to assess mutual associations between the biochemical results.
Results
Average serum concentrations of interferon-γ, neopterin, soluble interleukin-2 receptor and soluble CDS are listed in table 1. Serum neopterin, soluble interleukin-2 receptor and soluble CDS were significantly higher in patients than in healthy controls. Serum neopterin concentrations was above the upper limit of normal range (95th percentile of healthy controls) in ten patients (40%). Six patients (24%) had increased sol ble CDS, and 14 (56%) had increased soluble interleukin-2 receptor concentrations ( fig. 1 ). Endogenous interferon-γ was detectable in ten of 25 patients (40%). In one patient the serum concentrations of interferon-γ was 428 U/l; this is well above the upper limit of healthy controls which is 100 U/l.
Significant correlations were found between interferon-γ and neopterin concentrations, and between neopterin and soluble CD8 concentrations. No correlations existed between the other variables measured (tab. 2).
Seven of the ten patients with increased neopterin also had increased interferon-γ concentrations, as had 3 of the 15 patients with normal neopterin (p = 0.02, Fischer's exact test). All six patients with increased soluble CDS had increased soluble interleukin-2 receptor, seven often patients with normal soluble CDS also had increased soluble interleukin-2 receptor (p = 0.01). Five of six patients with increased soluble CDS had increased neopterin, but also six of 19 patients with normal soluble CDS had abnormal neopterin (p = not significant). There was no apparent association between increased or decreased soluble interleukin-2 receptor, and increased or decreased neopterin and interferon-γ.
Discussion
This study shows that a significant percentage of a panel of immune activation markers is elevated in patients with congestive heart failure. Serum concentrations of neopterin, soluble interleukin-2 receptor and soluble CDS were found to be increased in a variable but significant proportion of patients.
In vitro and in vivo data demonstrated a strong association between increased neopterin formation and the activation of cell mediated immunity (10, 11) . High neopterin concentrations are known to be closely associated with endogenous formation of cytokines during immune stimulation. Interferon-γ is the most potent inducer of neopterin formation and release by human monocytes/macrophages (11, 17) .
Endogenous interferon-γ was detected in less than half of the patients of this study. Although an optimized protocol was used, the sensitivity of the interferon-γ assay for the detection of immune activation was much lower than that of the other quantities measured in this study. Interferon-γ was outside the normal range in only one patient, who also had the highest neopterin concentration. Nevertheless, a significant association between increased interferon-γ and increased neopterin concentrations was found (tab. 2). It is possible that interferon-γ is released at local sites of inflammation and does not freely enter the blood stream. Similar observations were made earlier in patients with solid allograft rejections (18) . Interferon-γ may be released by activated T-cells and induce neopterin formation by monocytes/macrophages. Increased concentrations of soluble interleukin-2 receptor and soluble CDS found in some patients further support this conclusion. In vitro data show soluble interleukin-2 receptor and soluble CDS to be shed from activated and proliferating T-lymphocytes (19, 20) . In the shedding of soluble interleukin-2 receptor, it is not possible to distinguish between the subpopulations of T-cells involved, but increased soluble CDS concentrations point to a role of soluble CDS-positive cytotoxic/suppressor cells. Thus, our results favour the view that activated cytotoxic T-lymphocytes play a role in the release of interferon-γ in patients with congestive heart failure. In agreement with this assumption a correlation was found between soluble CDS and neopterin concentrations in the patients. Similar associations between the two quantities have also been described in patients with human immunodeficiency virus (HIV) infection (21) .
There were no strong correlations between soluble interleukin-2 receptor and the other variables. Notably, in earlier investigations on patients with HIV infection, the association between neopterin and soluble interleukin-2 receptor concentrations was also found to be rather weak (16, 22) . The size of the study is, however, too small for a final conclusion.
In earlier studies we found a significant association between increased neopterin concentrations and the stage of patients with congestive heart failure. (8) . In addition, several significant correlations were found between functional tests of left ventricles (such as enddiastolic volume and ejection fraction) and neopterin concentrations (8, 9) . The same abnormalities of left ventricular quantities are significantly associated with outcome in patients with dilated cardiomyopathy (23) . Thus, the correlations between neopterin con-centrations and other markers of immune stimulation found in this study further support a potential association between immune activation and the pathogenesis of congestive heart failure.
Our study shows that activation of the cellular immune system takes place in patients with congestive heart failure. Virus infection and/or autoimmune disease or both are involved in the aetiology of myocardial inflammation in patients with dilated cardiomyopathy or chronic myocarditis, aild immune activation may contribute to the spectrum of symptoms in patients and to progression of the disease.
